Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 10, 2005, Pages 4046-4051

  Ferris, Robert G ^a   Hazen, Richard J ^a   Roberts, Grace B ^a   St Clair, Marty H ^a   Chan, Joseph H ^a,b   Romines, Karen R ^a   Freeman, George A ^a   Tidwell, Jeffrey H ^a   Schaller, Lee T ^a   Cowan, Jill R ^a   Short, Steven A ^a   Weaver, Kurt L ^a   Selleseth, Dean W ^a   Moniri, Kelly R ^a   Boone, Lawrence R ^a  

^a GLAXOSMITHKLINE   (United States)

^b Development and Medical Affairs Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BENZOPHENONE DERIVATIVE; EFAVIRENZ; GW 678248; GW 695634; HUMAN SERUM ALBUMIN; NEVIRAPINE; OROSOMUCOID; PRODRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ASSAY; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN PURIFICATION; VIRUS INHIBITION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BENZOPHENONES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; HELA CELLS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; MOLECULAR STRUCTURE; MUTATION; OROSOMUCOID; REVERSE TRANSCRIPTASE INHIBITORS; SERUM ALBUMIN; U937 CELLS; VIRUS REPLICATION;

EID: 25844436257     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.10.4046-4051.2005     Document Type: Article

References (15)

1. Andries, K., H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwles, and M.-P. de Bethune. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
2. Averett, D. R. 1989. Anti-HIV compound assessment by two novel high capacity assays. J. Virol. 23:263-276.
3. Bacheler, L., S. Jeffrey, G. Hanna, R. D'Aquila, L. Wallace, K. Logue, B. Cordova, K. Hertogs, B. Larder, R. Buckery, D. Baker, K. Gallagher, H. Scarnati, R. Tritch, and C. Rizzo. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008.
4. Bacheler, L. T., E. D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Boiling, M. Aujay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutation selected inpatients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
5. Boffito, M., D. J. Black, T. F. Blaschke, M. Rowland, R. J. Bertz, J. G. Gerber, and V. Miller. 2003. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retrovir. 19:825-835.
6. Chan, J. H., G. A. Freeman, J. H. Tidwell, K. R. Romines, L. T. Schaller, J. R. Cowan, S. S. Gonzales, G. S. Lowell, C. W. Andrews III, D. J. Reynolds, M. StClair, R. J. Hazen, R. G. Ferris, K. L. Creech, G. B. Roberts, S. A. Short, K. Weaver, G. W. Koszalka, and L. R. Boone. 2004. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 47:1175-1182.
7. D'Aquila, R. T., J. M. Schapiro, F. Brun-Vezinet, B. Clotet, B. Conway, L. M. Demeter, R. M. Grant, V. A. Johnson, D. R. Kuritzkes, C. Loveday, R. W. Shafer, and D. D. Richman. 2003. Drug resistance mutations in HIV-1. Top. HIV Med. 11:92-96.
8. De Clercq, E. 2004. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future. Chem. Biodivers. 1:44-64.
9. Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. 1995. Mechanism of inhibition of reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:303-308.
10. 9a. Hazen, R. J., R. J. Harvey, M. H. St. Clair, R. G. Ferris, G. A. Freeman, J. H. Tidwell, L. T. Schaller, J. R. Cowan, S. A. Short, K. R. Romines, J. H. Chan, and L. R. Boone. Anti-human immunodeficiency virus type I activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals, against clinical isolate viruses, and in in vitro selection for resistance. Antimicrob. Agents Chemother., in press.
11. Huang, H., R. Chopra, G. Verdine, and S. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
12. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
13. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
14. Pauwels, R., E. De Clercq, J. Desmyter, J. Balzarini, P. Goubau, P. Herdewijn, H. Vanderhaeghe, and M. Vandeputte. 1987. Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J. Virol. Methods 16:171-185.
15. Robinson, L. H., R. E. Myers, B. W. Snowden, M. Tisdale, and E. D. Blair. 2000. HIV type 1 protcase cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retrovir. 16:1149-1156.